Haoxin Wu

Prof. Dr. Haoxin Wu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in British Journal of Pharmacology
Verified
Journal Article
Closed access
HZHailou Zhang
Hailou Zhang
YSYan Sun
Yan Sun
SYSuk-yu Yau
Suk-yu Yau
YZYanmeng Zhou
Yanmeng Zhou
XSXinxin Song
Xinxin Song
GCGang Chen
Gang Chen

2 March 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
RHRumin Huang
Rumin Huang
YSYan Sun
Yan Sun
RLRuiyi Liu
Ruiyi Liu
BZBoran Zhu
Boran Zhu
HZHailou Zhang
Hailou Zhang
HWHaoxin Wu
Haoxin Wu

25 May 2025 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
SZShihan Zhou
Shihan Zhou
SHShangbo Hua
Shangbo Hua
XCXinyi Chen
Xinyi Chen
MNMeiling Ni
Meiling Ni
JLJing Liu
Jing Liu
HWHaoxin Wu
Haoxin Wu
Background: Atherosclerosis (AS) is the most common cardiovascular disease (CVD), despite an overall declining incidence, AS remains a leading cause of death worldwide. The ZeXieYin formula (ZXYF), one of the thirteen formulas recorded in HuangDiNeiJin, a classical book of Traditional Chinese Medicine (TCM), has previously demonstrated efficacy in reducing blood lipids and combating AS. However, the precise mechanism by which it regulates blood lipids remains unclear. Given the close correlation between bile acid metabolism and cholesterol metabolism, it is imperative to elucidate the intrinsic mechanisms through which ZXYF treats AS. Purpose of the research: This study aims to investigate the pivotal role of enterohepatic bile acid circulation in enhancing intestinal barrier function and mitigating AS by ZXYF. Materials and methods: The AS model was established by subjecting male ApoE−/− mice to a high-fat diet (HFD). Moreover, to determine the impact of ZXYF on the integrity of the intestinal barrier, we quantified proinflammatory cytokines using RT-qPCR and ELISA. Additionally, we identified tight-junction proteins in the ileal tissues through IF. Finally, the intestinal flora metabolite and fecal bile acid composition were analyzed using 16S rRNA analysis, untargeted metabolomics analysis, and targeted metabolomics analysis. Results: The ZXYF significantly improved dyslipidemia and alleviated the formation of arterial plaques in AS mice. Furthermore, the administration of ZXYF resulted in a concurrent reduction in circulating lipopolysaccharide (LPS) levels and downregulation of pro-inflammatory cytokine mRNA expression in the ileum. Additionally, there was an enhancement observed in the expression of tight junction proteins within the intestinal tissue of AS mice. Further studies found that ZXYF significantly elevated the total bile acids (TBA) and total cholesterol (TC) levels in the fecal of AS mice. The untargeted and targeted metabolomic analyses further revealed that ZXYF exerts regulatory effects on bile acid phenotype by decreasing secondary bile acids (SBAs) levels through modulation of gut microbiota composition, such as enrichment of Akkermansia (AKK) abundance, and inhibition of enterohepatic circulation of bile acids. ZXYF specifically increased the expression of hepatic bile acid synthesis enzymes CYP7A1 by modulating the FXR/FGF15 signaling pathway, thereby promoting enhanced de novo bile acid synthesis and facilitating cholesterol catabolic excretion. Conclusion: The findings of our research indicate that ZXYF exerts a defensive role in the advancement of AS. The mechanism underlying the role of ZXYF in combating AS is closely associated with gut microbiota reshaping and regulation of enterohepatic bile acid circulation. Graphical

24 February 2023 in Pharmaceutical Biology
Verified
Journal Article
Open access
RLRuiyi Liu
Ruiyi Liu
YSYan Sun
Yan Sun
DDDong Di
Dong Di
XZXiyuan Zhang
Xiyuan Zhang
BZBoran Zhu
Boran Zhu
HWHaoxin Wu
Haoxin Wu
Previously, we found Alisma orientalis beverage (AOB), a classic traditional Chinese medicine (TCM) formulation, had the potential effect of treating atherosclerosis (AS). The underlying mechanism ...

4 June 2024 in Phytomedicine
Verified
Journal Article
Closed access
YSYan Sun
Yan Sun
HZHailou Zhang
Hailou Zhang
RLRuiyi Liu
Ruiyi Liu
YWYanqing Wang
Yanqing Wang
XZXiangrui Zhang
Xiangrui Zhang
HWHaoxin Wu
Haoxin Wu

11 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JLJing Liu
Jing Liu
SZShihan Zhou
Shihan Zhou
YWYanqing Wang
Yanqing Wang
JLJinling Liu
Jinling Liu
SSSuPing Sun
SuPing Sun
HWHaoxin Wu
Haoxin Wu